DUBLIN--(BUSINESS WIRE)--The "Drug
Delivery in Central Nervous System Diseases - Technologies, Markets and
Companies" report from Jain PharmaBiotech has been added to Research
and Markets' offering.
The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance.
Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS. Several carrier or transport systems, enzymes, and receptors that control the penetration of molecules have been identified in the BBB endothelium. Receptor-mediated transcytosis can transport peptides and proteins across the BBB. Methods are available to assess the BBB permeability of drugs at the discovery stage to avoid development of drugs that fail to reach their target site of action in the CNS.
The role of drug delivery is depicted in the background of various therapies for neurological diseases including drugs in development and the role of special delivery preparations. Pain is included as it is considered to be a neurological disorder. A special chapter is devoted to drug delivery for brain tumors. Cell and gene therapies will play an important role in the treatment of neurological disorders in the future.
The method of delivery of a drug to the CNS has an impact on the drug's
commercial potential. The market for CNS drug delivery technologies is
directly linked to the CNS drug market. Values are calculated for the
total CNS market and the share of drug delivery technologies. Starting
with the market values for the year 2016, projections are made to the
years 2021 and 2026. The markets values are tabulated according to
therapeutic areas, technologies and geographical areas.
Unmet needs for further development in CNS drug delivery technologies are identified according to the important methods of delivery of therapeutic substances to the CNS. Finally suggestions are made for strategies to expand CNS delivery markets. Besides development of new products, these include application of innovative methods of delivery to older drugs to improve their action and extend their patent life.
Profiles of 76 companies involved in drug delivery for CNS disorders are
presented along with their technologies, products and 99 collaborations.
These include pharmaceutical companies that develop CNS drugs and
biotechnology companies that provide technologies for drug delivery. A
number of cell and gene therapy companies with products in development
for CNS disorders are included. References contains over 420
publications that are cited in the report.
Key Topics Covered:
1. Basics of Drug Delivery to the Central Nervous System
2. Blood Brain Barrier
3. Methods of Drug Delivery to the CNS
4. Delivery of Cell, Gene and Antisense Therapies to the CNS
5. Drug Delivery for Treatment of Neurological Disorders
6. Drug delivery for brain tumors
7. Markets for Drug Delivery in CNS Disorders
For more information about this report visit https://www.researchandmarkets.com/research/pdtdbc/drug_delivery_in